Ignite Creation Date:
2025-12-24 @ 4:04 PM
Ignite Modification Date:
2025-12-28 @ 9:56 PM
Study NCT ID:
NCT05067166
Status:
AVAILABLE
Last Update Posted:
2024-12-17
First Post:
2021-09-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
Sponsor:
Ridgeback Biotherapeutics, LP
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
Ansuvimab EAP
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None